Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common acne gel help stop scarring hair loss?

NCT ID NCT05416333

Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This early-phase study tests whether azelaic acid gel, a topical medication already used for acne, can help women with central centrifugal cicatricial alopecia (CCCA) — a type of scarring hair loss that mainly affects Black women. Eighteen women will use the gel on their scalp once daily for six months, and researchers will measure changes in hair loss and regrowth using photos. The goal is to see if azelaic acid's anti-inflammatory effects might improve hair growth and reduce disease symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
azelaic acid gel (applied to the scalp once daily)
What this could lead to
If it works, this could point toward a new topical treatment option for CCCA, a scarring hair loss condition that currently has limited therapies.
What could go wrong
This is a very early, small pilot study with only 18 women. It is designed to see if azelaic acid shows any promise, not to prove effectiveness. Results may not apply to all patients or lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

18 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * women eighteen years of age or older * biopsy-proven and /or clinical diagnosis of CCCA Stage II-IV * on stable treatment without changes for at least three months * recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology Exclusion Criteria: * males

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central centrifugal cicatricial alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central centrifugal cicatricial alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central centrifugal cicatricial alopecia

Contacts and locations

Locations

  • Wake Forest University Health Scieces

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.